Combination therapy for locally advanced or recurrent pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced pancreatic cancer that cannot be removed by surgery, or your cancer came back only in the pancreas area after surgery (at least 6 months after finishing any post-surgery treatment).
- You have at least one tumor that can be measured on a scan.
- Your ability to take care of yourself is good (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
- You are between 18 and 75 years old and willing to use birth control if needed.
- You have not had any prior treatment with PD-1 or PD-L1 drugs, and you have not had radiation to the upper abdomen before.
- You do not have active autoimmune disease, uncontrolled serious medical conditions, or other cancers in the past 5 years (except for certain skin or localized cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.